inositol niacinate

cyclohexane-1,2,3,4,5,6-hexayl hexanicotinate cyclohexane-1,2,3,4,5,6-hexayl hexapyridine-3-carboxylate hexanicotinoyl inositol inositol hexanicotinate inositol nicotinate inositol, hexanicotinate, myo- inositoli nicotinas mesonex 2,3,4,5,6- pentakis((3-pyridinylcarbonyl)oxy)cyclohexyl nicotinate [2,3,4,5,6- pentakis(pyridine-3-carbonyloxy)cyclohexyl] pyridine-3-carboxylate 3- pyridinecarboxylic acid, 1,2,3,4,5,6-cyclohexanehexayl ester PubMed: Wax-matrix extended-release niacin vs inositol hexanicotinate: a comparison of wax-matrix, extended-release niacin to inositol hexanicotinate "no-flush" niacin in persons with mild to moderate dyslipidemia. PubMed: Biotransformation and pharmacokinetics of inositol hexanicotinate in rats. PubMed: Niacin: chemical forms, bioavailability, and health effects. PubMed: A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease. PubMed: Synthesis and antihyperlipidemic activity of acetylated derivative of ulvan from Ulva pertusa. PubMed: Determination of inositol hexanicotinate in rat plasma by high performance liquid chromatography with UV detection. PubMed: Dissolution profiles of nonprescription extended-release niacin and inositol niacinate products. PubMed: Purported benefits of inositol niacinate. PubMed: Antihyperlipidemic effects of different molecular weight sulfated polysaccharides from Ulva pertusa (Chlorophyta). PubMed: Inositol hexaniacinate. PubMed: The therapeutic efficacy of inositol nicotinate (Hexopal) in intermittent claudication: a controlled trial. PubMed: Does inositol nicotinate (Hexopal) influence intermittent claudication? A controlled trial. PubMed: A double blind randomised placebo controlled trial of hexopal in primary Raynaud's disease. PubMed: Inositol nicotinate in intermittent claudication. PubMed: Treatment of intermittent claudication with inositol nicotinate. PubMed: A double-blind placebo-controlled study of Hexopal in the treatment of intermittent claudication. PubMed: [Use of derivative resolution for the spectrophotometric analysis of drug mixtures. I. Determination of inositol hexanicotinate and bamethan sulfate in tablets]. PubMed: [Experience with the medical treatment of chronic cerebrovascular insufficiency: bamethan and inositol nicotinate versus placebo]. PubMed: Quantitative thermal imaging to assess inositol nicotinate treatment for Raynaud's syndrome. PubMed: Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs. PubMed: Lipids and lipoproteins in hyperlipidemia type IIa during treatment with different lipid lowering drugs. PubMed: Enzymatic hydrolysis of pentaerythritoltetranicotinate and meso-inositolhexanicotinate in blood and tissues. PubMed: [Comparative studies of the response of normolipemic and dyslipemic aged subjects to 2 forms of delayed-action nicotinic acid polyesters. Pentaerythrotol tetranicotinate and inositol hexanicotinate. Results of a controlled cross-over trial]. PubMed: A multiclinic double-blind trial of pyridinolcarbamate and inositol niacinate in ischemic ulcer due to chronic arterial occlusion. PubMed: [Pharmacokinetics of a combination of magnesium-chlorophenoxy-isobutyrate and meso-inositol hexanicotinate]. PubMed: [Clinical use of a thermal method for measuring peripheral blood flow according to A.M. Baptista (author's transl)]. PubMed: [Inositol hexanicotinate and its cholesteropenic effect]. PubMed: [Ulcers of the lower extremities. Treatment with inositol hexanicotinate]. PubMed: [Ocular changes experimentally induced in guinea pigs treated with an association of kallikrein and meso-inositol hexanicotinate]. PubMed: [On the fibrinolytic effect of the combination of kallikrein with meso-inositol hexanicotinate]. PubMed: The use of Hexanicotol (inositol niacinate) in peripheral vascular disease. PubMed: [Research on skin temperature and internal temperature in subjects with obliterating arteriopathy. Action of the association of kallikrein and meso-inositol hexanicotinate]. PubMed: [Clinical considerations and functional data on the use of the association of kallikrein and meso-inositol hexanicotinate in the therapy of obliterating arteriopathy]. PubMed: [The association of kallikrein and inositol hexanicotinate in the therapy of peripheral obliterating arteriopathy]. PubMed: [Effect of meso-inositol hexanicotinate on arteriosclerosis]. PubMed: [FIRST EXPERIENCES ON THE THERAPEUTIC ACTIVITY OF M-INOSITOL HEXANICOTINATE AND KALLIKREIN IN PERIPHERAL VASCULAR DISEASES AND IN CORONARY DISEASE]. PubMed: [APROPOS OF THE GASTROINTESTINAL ABSORPTION OF INOSITOL HEXANICOTINATE]. PubMed: [PHARMACOLOGICAL EXPERIMENTS WITH A COMBINATION OF KALLIKREIN AND MESO-INOSITOL HEXANICOTINATE]. PubMed: [CLINICAL TESTING OF MESO-INOSITOL-HEXANICOTINATE]. PubMed: [CLINICAL TRIAL OF A NEW NICOTINIC ACID DERIVATIVE, MESO-INOSITOL-HEXANICOTINATE, IN NEUROPSYCHIATRY]. PubMed: [INOSITOL HEXANICOTINATE IN THE THERAPY OF ULCUS CRURIS]. PubMed: [Therapy of peripheral arteriopathies with a compound with a base of inositol hexanicotinate]. PubMed: Inositol niacinate as a peripheral vasodilator. PubMed: [Apropos of the hypocholesterolemic effects of nicotinic acid. Experimental investigations of such a compound and of inositol hexanicotinate]. PubMed: Inositol hexanicotinate for improved nicotinic acid therapy. Preliminary report. PubMed: Speripheral vascular disease in general practice. Some experiences with meso-inositol-hexanicotinate.